Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab PK/PD and safety study in children aged 6-11 years with eosinophilic asthma
ChiCTR2600135822Phase 3Not yet recruiting
- Sponsor
- West China Second University Hospital
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of depemokimab in asthma, sponsored by West China Second University Hospital. Primary endpoint: Pharmacokinetics of depemokimab. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2600135822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135822.